



A Phase 1a/b Clinical Trial  
of **LY3866288** for the  
Treatment of Cancer With a  
Change in the **FGFR3** Gene

- 
- Looking for participants

## What is the purpose of this study?

To learn if LY3866288 may be used to treat solid tumors that have a change in the FGFR3 gene.

## What is FGFR3?

- **FGFR3** stands for **Fibroblast Growth Factor Receptor 3**
- FGFR3 is a gene that everyone has but undergoes a change in some people, resulting in cancer in the bladder, urinary tract, or other areas of the body
- To look for a change(s) in the FGFR3 gene, a doctor will perform a test using the patient's blood and/or tumor tissue

## Who can participate in the study?

This study is for patients:

- who are 18 years or older
- diagnosed with **metastatic urothelial carcinoma** or another **solid tumor** with a change in the **FGFR3** gene
- who have undergone all standard treatments for the type of cancer they have

Please look at the study website for a complete list of what is needed to participate.

## What is the plan for the study?

- This is an **open-label study**, meaning both doctors and patients will know what treatment is being given
- All patients will receive LY3866288. No placebo will be given in this study\*



**LY3866288**

Daily oral medication

\*LY3866288 in combination with pembrolizumab, or enfortumab vedotin plus pembrolizumab may also be studied.

## What is the main goal of the study?

- The main goal of the study is to learn about the safety, side effects, and effectiveness of LY3866288

Please look at the study website for a complete list of the study goals.

If you have bladder cancer or another solid tumor with a change in the FGFR3 gene, consider learning more about this study.

- Print out and bring this sheet to your next appointment with your doctor
- At certain sites, patients may be eligible to receive reimbursement for travel costs associated with study participation
- Patients can stop being a part of the study at any time



**For more information:**

<https://trials.lilly.com/en-US/trial/367675>

**Lilly Trials Support:** [ClinicalTrials.gov@lilly.com](mailto:ClinicalTrials.gov@lilly.com)

The use of LY3866288 is experimental. Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.

